Clinical Research Director
Clinical Research Director (MD role) Central London £130k + bonus + LTIP + benefits Only Medics with our executive search firm CP Global Search is pleaed to have one of the world's leading AI firms on a retained search. This is an exciting opportunity to join a rapidly growing high profile London based Tech-Bio company applying artificial intelligence approaches to disrupt drug discovery and development, This is a seriously well funded business which has candidates at IIb and a pipeline of additional programmes ready to develop. They require an experienced Physician to lead and mange early phase clinical trails. You will report directly to the CMO and will have an autonomous role leading and directing a company wide collaborative effort. Key experience as follows: -Provide medical and clinical development expertise to project level activities with multiple Clinical projects in late preclinical through to Phase 2B.. -Working with external experts, KOls/Ad Boards, participation in planned regular calls with Clinical and Regulatory CROs and service providers, and providing input to communications with Ethics committees, Regulators, and Investigators. -Drafting Clinical documents including Investigator Brochures, Protocols, and Clinical Development plans, and involvement in drafting Target Profiles (TPPs), including interaction with Commercial/Business Development colleagues. -Provide clinical insight, medical needs assessment, and clinical development expertise to pre Clinical Projects and AI Technology tool development. -Support Vendor evaluation and selection processes ( i.e. Bid defence) Requirements MD with significant clinical research experience Broad range of therapy area alignment Ability to direct and drive forward early phase clinical trials - Phase 1 & 2 Aptitude to collaborate across the business with different expertise areas In summary this is a genuine ground breaking, industry disrupting business. The successful candidate will be in at the start of a major international success. The firm has very solid funding and an enviable pipeline in the rare disease area.